144 related articles for article (PubMed ID: 34890736)
1. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Saifi O; Breen WG; Lester SC; Rule WG; Stish B; Rosenthal A; Munoz J; Herchko SM; Murthy HS; Lin Y; Bansal R; Hathcock MA; Bennani NN; Paludo J; Wang Y; Khurana A; Bisneto JCV; Johnston PB; Ansell SM; Iqbal M; Tun H; Ayala E; Kharfan-Dabaja MA; Hoppe BS; Peterson JL
Radiother Oncol; 2022 Jan; 166():171-179. PubMed ID: 34890736
[TBL] [Abstract][Full Text] [Related]
2. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
[TBL] [Abstract][Full Text] [Related]
3. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.
Saifi O; Breen WG; Lester SC; Rule WG; Stish BJ; Rosenthal A; Munoz J; Lin Y; Bansal R; Hathcock MA; Bennani NN; Paludo J; Khurana A; Villasboas JC; Johnston PB; Ansell SM; Iqbal M; Moustafa MA; Murthy HS; Kharfan-Dabaja MA; Hoppe BS; Peterson JL
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):999-1007. PubMed ID: 36563910
[TBL] [Abstract][Full Text] [Related]
4. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
Saifi O; Lester SC; Breen WG; Rule WG; Lin Y; Bennani NN; Rosenthal A; Munoz J; Murthy HS; Kharfan-Dabaja MA; Peterson JL; Hoppe BS
Am J Hematol; 2024 Jan; 99(1):124-134. PubMed ID: 37950857
[TBL] [Abstract][Full Text] [Related]
5. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
[TBL] [Abstract][Full Text] [Related]
6. CNS Bridging Radiotherapy Achieves Rapid Cytoreduction Prior to CAR T Cell Therapy for Aggressive B-Cell Lymphoma.
Cederquist G; Schefflein J; Devlin SM; Shah GL; Shouval R; Hubbeling H; Tringale KR; Alarcon Tomas A; Fregonese B; Hajj C; Boardman AP; Luna De Abia A; Corona M; Cassanello G; Dahi PB; Lin RJ; Ghione P; Salles GA; Perales MA; Palomba ML; Falchi L; Scordo M; Grommes C; Yahalom J; Imber BS
Blood Adv; 2024 Jun; ():. PubMed ID: 38861344
[TBL] [Abstract][Full Text] [Related]
7. Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy.
Zhou L; Li P; Ye S; Tang X; Wang J; Liu J; Liang A
Front Med; 2020 Dec; 14(6):786-791. PubMed ID: 32789732
[TBL] [Abstract][Full Text] [Related]
8. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes.
Figura NB; Sim AJ; Jain MD; Chavez JC; Robinson TJ
Expert Rev Hematol; 2022 Dec; 15(12):1023-1030. PubMed ID: 36369950
[TBL] [Abstract][Full Text] [Related]
9. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
10. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):17-22. PubMed ID: 11163493
[TBL] [Abstract][Full Text] [Related]
11. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
Imber BS; Sadelain M; DeSelm C; Batlevi C; Brentjens RJ; Dahi PB; Giralt S; Park JH; Sauter C; Scordo M; Shah G; Perales MA; Palomba ML; Yahalom J
Br J Haematol; 2020 Jul; 190(1):45-51. PubMed ID: 32135029
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant high-dose-rate brachytherapy after external beam radiotherapy in nasopharyngeal carcinoma.
Ozyar E; Yildz F; Akyol FH; Atahan IL
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):101-8. PubMed ID: 11777627
[TBL] [Abstract][Full Text] [Related]
13. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Tseng YD; Chen YH; Catalano PJ; Ng A
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):223-31. PubMed ID: 25835625
[TBL] [Abstract][Full Text] [Related]
14. Late complications after postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases with application of linear-quadratic model.
Jereczek-Fossa B; Jassem J; Nowak R; Badzio A
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):329-38. PubMed ID: 9607348
[TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
Yegya-Raman N; Wright CM; LaRiviere MJ; Baron JA; Lee DY; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Maity A; Facciabene A; Paydar I; Plastaras JP
Clin Transl Radiat Oncol; 2023 Mar; 39():100587. PubMed ID: 36718252
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
18. Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure.
Russo AL; Chen YH; Martin NE; Vinjamoori A; Luthy SK; Freedman A; Michaelson EM; Silver B; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):121-7. PubMed ID: 23414765
[TBL] [Abstract][Full Text] [Related]
19. High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy.
Mundt AJ; Williams SF; Hallahan D
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):617-25. PubMed ID: 9336141
[TBL] [Abstract][Full Text] [Related]
20. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.
Saleh K; Michot JM; Schernberg A; Lazarovici J; Chahine C; Danu A; Khalife-Saleh N; Rossignol J; Ghez D; Martin V; Mazeron R; Fermé C; Boros A; Ribrag V; Girinsky T
Cancer Med; 2020 Jun; 9(11):3725-3732. PubMed ID: 32249547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
